Given the lack of innovation and over-reliance on existing products, I recommend a "sell" rating for Haleon, questioning its standalone success and justification for current valuation. GSK chose ...

GSK, its consumer health spin-off Haleon, and Sanofi could be on the ... Some voluntarily took their products off the market as soon as the NDMA finding was reported by the FDA.

Haleon missed third-quarter revenue and profit expectations on Thursday, hit by a stronger pound and lower sales of its ...

Currency fluctuations meant Haleon saw year-on-year reported revenue slip 0.6% to £2.78bn in the third quarter, below ...

Despite pressure on consumer spending, consumers prioritise trusted brands for their health-related needs and Haleon is a ...

Haleon backed its full-year guidance despite ... The British consumer-healthcare business—which was spun out of GSK and is partly owned by Pfizer—said Thursday that revenue for the quarter ...

Subsequently, in July 2022, GSK spun off Haleon as an independent publicly ... driven by strong demand for the company’s oral care products and vitamins. Moving forward, the company expects ...

Haleon is a global consumer health company based in the UK, focused on developing and marketing over-the-counter health products. The company was formed as a spin-off from GSK (GlaxoSmithKline ...

GSK divested Haleon, its consumer group ... of 4% over the next five years (including joint ventures), with new products such as Shingrix and Arexvy offsetting generic competition due to patent ...